Candel Therapeutics
Price chart
Anonymous reader poll. Unscientific, not investment advice.
✦ StockVane Quant Insights how this is computed
- Below its 200-day average or in the bottom third on momentum — the strategy is out of it.
- Signal has read SELL for 2 weeks.
- Its last 5 Sell calls were followed by roughly flat moves (+1%) three months out.
- Recent price momentum is -22.6% on average (3-month/1-year).
- Main-fund capital flow has been a net outflow over the last 45 sessions.
- Short interest has fallen to 17.1% of float.
- Analyst tilt is Buy.
- Price is below its 20-day average and below its 60-day average.
- The 20-day average is below the 60-day average, a short-term downtrend.
Computed by a StockVane algorithm from historical price, valuation and analyst data - not a person, not a forecast guarantee, and not investment advice.
Factor grades
Ranked against 2849 U.S. stocks StockVane covers.
Last computed: 2026-11-21 14:27 UTC
Data coverage: 4 of 6 factors. Missing data is not a zero score.
The radar needs all six factors. Available grades are shown below.
Valuation N/A
How expensive the stock is versus earnings, sales and its own 5-year history.
Not enough data to grade this factor.
Growth N/A
How fast revenue, profit and free cash flow are compounding.
Not enough data to grade this factor.
Profitability F
How much profit the business keeps from each dollar of sales and capital.
| Operating margin | -27,739.2% | Better than 0% |
| Net margin | -15,035.2% | Better than 1% |
| Return on equity | -64.6% | Better than 7% |
| Return on invested capital | -44.2% | Better than 7% |
Momentum C-
Recent price strength, skipping the latest month to avoid short-term noise.
| 3-month return | -61.6% | Better than 2% |
| 6-month return | -36.9% | Better than 14% |
| 12-month return (ex latest month) | 84.2% | Better than 93% |
| Distance below 52-week high | 64.0% | Better than 8% |
Financial Health C+
Balance-sheet strength: leverage, liquidity and interest coverage.
| Current ratio | 13.5x | Better than 96% |
| Debt to assets | 39.2% | Better than 28% |
| Interest coverage | -17.0x | Better than 10% |
Analyst View A+
What the Street thinks: share of Buy ratings and upside to the average target.
| Analysts rating Buy | 100.0% | Better than 77% |
| Upside to average target | 233.9% | Better than 96% |
Grades are relative rankings, not forecasts: A+ is the top 5% of the covered stocks on a factor, F the bottom 3%. Valuation is not adjusted for sector. Background recomputation is scheduled every 6 hours; actual computation time is shown above, and source datasets have different reporting dates. Not investment advice or tailored to your financial situation.
Performance
Key statistics
Price & volume
- Prev close
- 5.13
- Open
- 5.00
- Day range
- 4.90 - 5.31
- Avg price
- 5.04
- Volume
- 1.73M
- Turnover
- 8.71M
- Turnover ratei
- 2.52%
- Volume ratioi
- 0.60
- Amplitudei
- 7.99%
- 52-week rangei
- 4.35 - 14.00
Valuation
- P/Ei
- -7.00
- P/E (TTM)i
- -3.29
- P/Bi
- 3.01
- EPSi
- -0.72
- Book value / shi
- 1.68
- Net profit
- -56.48M
- Net assets
- 131.55M
Share structure
- Market cap
- 395.37M
- Float capi
- 345.58M
- Shares out
- 78.45M
- Float sharesi
- 68.57M
Dividend & listing
- Div yield (TTM)i
- 0.00%
- Dividend (TTM)
- 0.00
- Listing date
- 2021-07-27
64.0% below the 52-week high
Trading activity
Net capital flow main funds, last 45 sessions
-3.37M net over the window
Short interest
- Shares short
- 13.09M
- % of floati
- 17.10%
- Days to coveri
- 13.31
- As of
- 2026-10-30
Frequently asked questions
What is the current stock price of Candel Therapeutics (CADL)?
Candel Therapeutics last traded at 5.04. This page shows a periodic quote snapshot. Check the displayed quote time.
What is Candel Therapeutics's market cap?
About 395.37M.
What is the P/E ratio of Candel Therapeutics?
The trailing twelve-month P/E is -3.29. The Valuation tab shows it against the stock's own five-year range.
Does Candel Therapeutics pay a dividend?
Candel Therapeutics does not currently pay a regular dividend.
Is Candel Therapeutics a buy according to analysts?
The consensus of 6 analysts is a Buy rating, with an average 12-month price target of 16.83, which implies 233.9% upside from the current price. This is not investment advice.
What is Candel Therapeutics's StockVane Quant Rating?
The StockVane Momentum strategy currently rates Candel Therapeutics a D (Sell). Below its 200-day average or in the bottom third on momentum — the strategy is out of it. Not investment advice.
Quote time 2026-11-20 20:02:29 · For reference only, not investment advice and not tailored to your situation.
Candel Therapeutics discussion 0 comments